The Chhattisgarh health department, committed to a zero-tolerance policy regarding quality control, has issued a show cause notice to M/s. Effi Parenterals, potentially leading to the company’s blacklisting. This action follows the discovery of significant quality issues in their supplied medication.
Before distributing medicines to health institutions from drug warehouses, the department conducts quality tests on random samples from all batches supplied by vendors. These tests are performed in NABL-accredited laboratories to ensure that only drugs that pass the tests are distributed.
As part of this process, the Albendazole Tablets IP 400 mg (Drug Code – D12) batches PGT25451, PGT25450, PGT25480, and PGT25229 supplied by M/s. Effi Parenterals to the warehouse were tested at the State Drug Testing and Research Laboratory, Raipur, before being sent to hospitals. The tests revealed that these batches failed to meet the quality standards. Consequently, adhering to its zero-tolerance policy, the department has issued a show cause notice to the firm, proposing to blacklist it. The firm has also been instructed to recall all the failed batches of the drug from the drug warehouses.
In addition to these batches, the firm had previously supplied 14 batches of Albendazole Tablets IP 400 mg. These batches were distributed to health institutions after passing the NABL test reports.
